Loading...
Eli Lilly and Company
LLY.DE•XETRA
HealthcareDrug Manufacturers - General
€674.40
€4.90(0.73%)
Eli Lilly and Company (LLY.DE) Financial Performance & Statements
Review Eli Lilly and Company’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
32.00%
↑ 32.00%
Operating Income Growth
69.50%
↑ 69.50%
Net Income Growth
102.08%
↑ 102.08%
Operating Cash Flow Growth
107.96%
↑ 107.96%
Operating Margin
39.38%
↑ 39.38%
Gross Margin
81.70%
↑ 81.70%
Net Profit Margin
22.66%
↑ 22.66%
ROE
76.92%
↑ 76.92%
ROIC
32.53%
↑ 32.53%
Eli Lilly and Company (LLY.DE) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Eli Lilly and Company stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $13.53B | $11.44B | $11.30B | $8.77B |
| Cost of Revenue | $2.40B | $2.17B | $2.17B | $1.67B |
| Gross Profit | $11.13B | $9.27B | $9.13B | $7.09B |
| Gross Profit Ratio | $0.82 | $0.81 | $0.81 | $0.81 |
| R&D Expenses | $3.21B | $2.73B | $2.71B | $2.52B |
| SG&A Expenses | $2.42B | $2.10B | $2.003B | $1.84B |
| Operating Expenses | $5.98B | $4.83B | $4.83B | $4.36B |
| Total Costs & Expenses | $8.38B | $7.005B | $7.00B | $6.14B |
| Interest Income | $44.30M | $47.80M | $37.30M | $45.80M |
| Interest Expense | $224.70M | $192.70M | $183.60M | $179.60M |
| Depreciation & Amortization | $466.80M | $466.80M | $414.40M | $400.60M |
| EBITDA | $6.15B | $2.25B | $4.12B | $3.12B |
| EBITDA Ratio | $0.45 | $0.20 | $0.36 | $0.36 |
| Operating Income | $5.15B | $4.43B | $4.30B | $2.74B |
| Operating Income Ratio | $0.38 | $0.39 | $0.38 | $0.31 |
| Other Income/Expenses (Net) | -$110.10M | -$2.85B | -$786.90M | -$199.50M |
| Income Before Tax | $5.04B | $1.59B | $3.52B | $2.54B |
| Income Before Tax Ratio | $0.37 | $0.14 | $0.31 | $0.29 |
| Income Tax Expense | $628.90M | $618.10M | $550.20M | $293.20M |
| Net Income | $4.41B | $970.30M | $2.97B | $2.24B |
| Net Income Ratio | $0.33 | $0.08 | $0.26 | $0.26 |
| EPS | $4.88 | $1.08 | $3.29 | $2.49 |
| Diluted EPS | $4.88 | $1.07 | $3.28 | $2.48 |
| Weighted Avg Shares Outstanding | $903.65M | $901.00M | $900.90M | $900.80M |
| Weighted Avg Shares Outstanding (Diluted) | $903.16M | $905.00M | $904.20M | $903.80M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan